Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report
- 17 January 2006
- journal article
- case report
- Published by Wiley in International Journal of Dermatology
- Vol. 45 (6) , 751-753
- https://doi.org/10.1111/j.1365-4632.2006.02751.x
Abstract
Background A 31‐year‐old man who has suffered since age 3 from diffuse cutaneous leishmaniasis (DCL), a disease with profound physical and psychosocial repercussions and no effective treatment at present, was treated with miltefosine.Methods The patient was treated for 120 days, 100 mg/day for 1 week, then 150 mg/day subsequently.Results Lesions were free of parasites at 43 days, and no signs of infiltration were present at day 76. No adverse side effects were observed.Conclusions The dramatic clinical effect of miltefosine in this patient appears to fully justify further evaluation of this experimental therapy in DCL.Keywords
This publication has 6 references indexed in Scilit:
- Oral Miltefosine for Leishmaniasis in Immunocompromised Patients: Compassionate Use in 39 Patients with HIV InfectionClinical Infectious Diseases, 2004
- Miltefosine for New World Cutaneous LeishmaniasisClinical Infectious Diseases, 2004
- Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin BActa Tropica, 2001
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- The clinical and immunological spectrum of American cutaneous leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 1993
- Diffuse cutaneous leishmaniasis: A disease due to an immunological defect of the hostTransactions of the Royal Society of Tropical Medicine and Hygiene, 1972